For treating bipolar disorder, investigators have explored single strategies targeting dopamine receptors or the glycogen synthase kinase-3 (GSK-3) pathway. Researchers at Istituto Italiano di Tecnologia and collaborators have used computational modeling and structure determination to improve on a prototype small molecule capable of simultaneously activating the dopamine D3 receptor while inhibiting GSK-3β.

An analysis of more than 1,000 small molecules has identified dozens of compounds that could be effective to treat Marfan syndrome (MFS), an inherited disorder affecting connective tissue, primarily in the heart and blood vessels, the skeleton, and the eyes. In particular, the researchers from Cambridge University found that glycogen synthase kinase-3β (GSK-3β) could be a target to develop new therapies based on its inhibition.